Acute Intracerebral Hemorrhage

Journal publishes results of acute intracerebral hemorrhage study

Published in Gene Therapy Weekly, March 24th, 2005

Novo Nordisk Inc. announced the results of a recently completed clinical trial of NovoSeven Coagulation Factor VIIa (Recombinant) in patients with acute intracerebral hemorrhage (ICH) as published in the New England Journal of Medicine (NEJM).

The NEJM article, "Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage," presents the results of the largest clinical trial ever conducted with a pharmacologic agent for the treatment of ICH. The study found a reduction in hematoma growth (bleeding in the brain), decreased mortality, and improvement in neurological and clinical outcomes in patients treated with NovoSeven compared to placebo.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry